AstraZeneca hikes earnings forecast after surging cancer drug sales

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Louis Goss is a MarketWatch reporter based in London.

Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.

The uptick in AstraZeneca’s revenues was largely driven by a 17% increase in sales of cancer drugs at constant exchange rates, to $4.66 billion, on the back of 53% higher sales of its cancer immunotherapy drug Imfinzi. Excluding lower sales of COVID vaccines across the globe, AstraZeneca’s sales increased in all regions worldwide, apart from China, as the firm showed particularly strong growth in emerging markets.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 3. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Geopolitical clash could still spark market incident, Deutsche Bank CEO warnsLouis Goss is a MarketWatch reporter based in London.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »

Uber notches earnings beat but comes up short on the top lineEmily Bary is a MarketWatch news editor based in New York.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »